Myriad sues Ambry over cancer gene screening tests
10-07-2013
Ambry Genetics, the laboratory sued last month by biotech company Myriad over patents covering the BRCA1 and BRCA2 genes, has hit back with antitrust claims.
If you have already subscribed please login.
If you have any technical issues please email tech support.
ambry genetics, myriad genetics, brca1, brca2, prometheus
